CytoMed TherapeuticsGDTC.OValuation Analysis

As of Oct 16, 2026, CytoMed Therapeutics (GDTC.O) trades at a negative P/E (-3.84x, due to a recent net loss), P/B of 2.71x, P/S of 41.40x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/B sits at the 27th percentile over the trailing 10Y window (vs. 31st percentile over 3Y); P/S sits at the 9th percentile over the trailing 10Y window (vs. 9th percentile over 3Y).
Cross-sectional valuation: its P/B ranks at the 57th percentile within its industry and the 68th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
The P/B percentile sits lower within its industry than across the market as a whole — relatively cheaper next to direct peers. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. CytoMed Therapeutics operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.